AU2014243783B2 - Antibody formulations - Google Patents

Antibody formulations Download PDF

Info

Publication number
AU2014243783B2
AU2014243783B2 AU2014243783A AU2014243783A AU2014243783B2 AU 2014243783 B2 AU2014243783 B2 AU 2014243783B2 AU 2014243783 A AU2014243783 A AU 2014243783A AU 2014243783 A AU2014243783 A AU 2014243783A AU 2014243783 B2 AU2014243783 B2 AU 2014243783B2
Authority
AU
Australia
Prior art keywords
formulation
antibody
amount
trehalose
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014243783A
Other languages
English (en)
Other versions
AU2014243783A1 (en
Inventor
Yatin Gokarn
Thomas PATAPOFF
Isidro E. Zarraga
Jonathan ZARZAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51625441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014243783(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2014243783A1 publication Critical patent/AU2014243783A1/en
Assigned to GENENTECH, INC. reassignment GENENTECH, INC. Amend patent request/document other than specification (104) Assignors: GENETECH, INC.
Application granted granted Critical
Publication of AU2014243783B2 publication Critical patent/AU2014243783B2/en
Priority to AU2019201566A priority Critical patent/AU2019201566B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Endocrinology (AREA)
AU2014243783A 2013-03-13 2014-03-13 Antibody formulations Ceased AU2014243783B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019201566A AU2019201566B2 (en) 2013-03-13 2019-03-06 Antibody formulations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780899P 2013-03-13 2013-03-13
US61/780,899 2013-03-13
PCT/US2014/026824 WO2014160490A1 (en) 2013-03-13 2014-03-13 Antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019201566A Division AU2019201566B2 (en) 2013-03-13 2019-03-06 Antibody formulations

Publications (2)

Publication Number Publication Date
AU2014243783A1 AU2014243783A1 (en) 2015-10-01
AU2014243783B2 true AU2014243783B2 (en) 2018-12-13

Family

ID=51625441

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014243783A Ceased AU2014243783B2 (en) 2013-03-13 2014-03-13 Antibody formulations
AU2019201566A Ceased AU2019201566B2 (en) 2013-03-13 2019-03-06 Antibody formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019201566A Ceased AU2019201566B2 (en) 2013-03-13 2019-03-06 Antibody formulations

Country Status (17)

Country Link
US (3) US10010611B2 (enExample)
EP (2) EP3744345B1 (enExample)
JP (2) JP6511609B2 (enExample)
KR (2) KR102048512B1 (enExample)
CN (2) CN105209069B (enExample)
AR (1) AR095396A1 (enExample)
AU (2) AU2014243783B2 (enExample)
BR (1) BR112015022210A8 (enExample)
CA (1) CA2906057A1 (enExample)
IL (2) IL240886B (enExample)
MX (2) MX365567B (enExample)
MY (2) MY185551A (enExample)
NZ (2) NZ751452A (enExample)
RU (2) RU2019120404A (enExample)
SG (2) SG10201913932VA (enExample)
WO (1) WO2014160490A1 (enExample)
ZA (2) ZA201506981B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209069B (zh) 2013-03-13 2019-08-23 豪夫迈·罗氏有限公司 抗体配制剂
SG11201701821QA (en) 2014-09-15 2017-04-27 Genentech Inc Antibody formulations
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
AU2016210918A1 (en) * 2015-01-28 2017-07-13 Pfizer Inc., Stable aqueous anti- vascular endothelial growth factor (VEGF) antibody formulation
WO2017100722A1 (en) * 2015-12-09 2017-06-15 Cedars-Sinai Medical Center Methods for treating nephrotic syndrome
CN105920600A (zh) * 2016-04-19 2016-09-07 上海景泽生物技术有限公司 一种稳定的抗vegf抗体制剂及其用途
CN109415440B (zh) 2016-06-27 2022-12-06 莫佛塞斯公司 抗-cd19抗体制剂
CN107384932B (zh) 2016-08-31 2020-10-20 北京天广实生物技术股份有限公司 抗人cd20人源化单克隆抗体mil62、其制备方法及用途
EP3541413A2 (en) 2016-11-21 2019-09-25 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
CN108686204A (zh) * 2017-04-07 2018-10-23 浙江海正药业股份有限公司 包含组氨酸缓冲体系的英夫利西单抗组合物
US11865175B1 (en) 2017-04-28 2024-01-09 Cedars-Sinai Medical Center Post-transplantation prophylaxis and treatments for antibody-mediated rejection of solid organ transplant
CN107899020A (zh) * 2017-08-11 2018-04-13 百奥泰生物科技(广州)有限公司 Cd20阳性疾病治疗的化合物及方法
CN107881160A (zh) * 2017-08-11 2018-04-06 百奥泰生物科技(广州)有限公司 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法
MA50670A (fr) * 2017-09-29 2020-08-05 Janssen Biotech Inc Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose
EP3730126B1 (en) * 2017-12-22 2025-05-14 Samsung Bioepis Co., Ltd. Liquid composition comprising vegf antagonist
EP3837035B1 (en) 2018-08-16 2026-05-20 Emd Millipore Corp Closed bioprocessing device
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
WO2021068971A1 (en) * 2019-10-12 2021-04-15 Bio-Thera Solutions, Ltd. Anti-cd20 antibody formulation and use of anti-cd20 antibody for treatment of cd20 positive diseases
AU2021232369B2 (en) * 2020-03-04 2025-06-05 Shanghai Henlius Biotech, Inc. Pharmaceutical formulation comprising bevacizumab
WO2022265591A1 (en) * 2021-06-18 2022-12-22 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of bevacizumab

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121615A2 (en) * 2007-03-30 2008-10-09 Medimmune, Inc. Antibody formulation
US20090162352A1 (en) * 2007-12-21 2009-06-25 Michael Adler Antibody formulation
WO2011012637A2 (en) * 2009-07-31 2011-02-03 F. Hoffmann-La Roche Ag Subcutaneous anti-her2 antibody formulation

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
DE3228284C2 (de) 1982-07-29 1986-11-27 Messerschmitt-Bölkow-Blohm GmbH, 8000 München Niederhaltevorrichtung für entfaltbare Funktionselemente
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6395492B1 (en) 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
DK1975181T3 (da) 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP2095873A1 (en) 1996-08-30 2009-09-02 Upfront Chromatography A/S Isolation of immunoglobulins
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US20080318254A9 (en) 1997-03-10 2008-12-25 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
IL132240A0 (en) 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
DE69832970T2 (de) 1997-04-07 2006-08-10 Genentech, Inc., South San Francisco Humanisierte antikörper und verfahren zu ihrer herstellung
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
AU754808B2 (en) 1999-03-30 2002-11-28 Amgen Fremont Inc. Method for preparing Monoclonal Antibody
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
JP2005519580A (ja) 2001-05-16 2005-07-07 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ 非ヒト動物由来のヒト抗肺炎球菌抗体
IL160358A0 (en) 2001-08-23 2004-07-25 Genmab As Human antibodies specific for interleukin 15 (il-15)
KR20110017020A (ko) 2002-10-17 2011-02-18 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
AU2004205898B2 (en) 2003-01-17 2009-11-19 The Research Foundation Of State University Of New York Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
CZ308720B6 (cs) 2003-01-22 2021-03-24 Roche Glycart Ag Fúzní konstrukty a jejich použití pro přípravu protilátek se zvýšenou vazebnou afinitou k receptorům Fc a efektorovou funkcí
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
DE10314595B4 (de) 2003-03-31 2006-05-04 Infineon Technologies Ag Verfahren zur Herstellung von Transistoren unterschiedlichen Leitungstyps und unterschiedlicher Packungsdichte in einem Halbleitersubstrat
CA2526398C (en) 2003-05-21 2014-07-15 Medarex, Inc. Human monoclonal antibodies against bacillus anthracis protective antigen
JP4810427B2 (ja) 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
NZ621449A (en) 2003-05-30 2015-07-31 Genentech Inc Treatment with anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
RU2482132C2 (ru) 2005-08-26 2013-05-20 Роше Гликарт Аг Модифицированные антигенсвязывающие молекулы с измененной клеточной сигнальной активностью
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US20090110688A1 (en) 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
RU2010138799A (ru) * 2008-02-21 2012-03-27 Иста Фармасьютикалз (Us) Офтальмологические нестероидные противовоспалительные средства в качестве адъювантов
CA2736864C (en) 2008-09-19 2020-10-13 Pfizer Inc. Stable liquid antibody formulation
US9127273B2 (en) * 2009-01-13 2015-09-08 The Board Of Regents Of The University Of Texas System UNC-45A splice variants based cancer diagnostics and therapeutics
RU2011140486A (ru) 2009-03-06 2013-04-20 МЕДИММЬЮН, ЭлЭлСи Композиции, содержащие гуманизированные антитела к cd19
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
BR112012013093A2 (pt) * 2009-12-21 2017-12-12 Genentech Inc ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável
PT2542590T (pt) 2010-03-05 2017-08-31 Univ Johns Hopkins Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados
US20130209465A1 (en) * 2010-07-30 2013-08-15 Arecor Ltd. Stabilized Aqueous Antibody Compositions
MX341076B (es) * 2011-03-31 2016-08-04 Merck Sharp & Dohme Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
GB201107170D0 (en) * 2011-04-28 2011-06-15 Clark Michael Binding molecules with biased recognition
WO2013063510A1 (en) 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
FR2995214B1 (fr) 2012-09-10 2014-11-21 Adocia Solution a viscosite reduite de proteine a concentration elevee
CN105209069B (zh) 2013-03-13 2019-08-23 豪夫迈·罗氏有限公司 抗体配制剂
SG11201701821QA (en) 2014-09-15 2017-04-27 Genentech Inc Antibody formulations
CA3026668C (en) 2018-08-22 2020-06-30 Gulfstream Inc. Bubble generation system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121615A2 (en) * 2007-03-30 2008-10-09 Medimmune, Inc. Antibody formulation
US20090162352A1 (en) * 2007-12-21 2009-06-25 Michael Adler Antibody formulation
WO2011012637A2 (en) * 2009-07-31 2011-02-03 F. Hoffmann-La Roche Ag Subcutaneous anti-her2 antibody formulation

Also Published As

Publication number Publication date
AU2019201566B2 (en) 2020-12-10
JP2016515124A (ja) 2016-05-26
KR102127085B1 (ko) 2020-06-26
CN105209069A (zh) 2015-12-30
WO2014160490A1 (en) 2014-10-02
SG10201913932VA (en) 2020-03-30
WO2014160490A8 (en) 2015-07-30
MX2015011425A (es) 2016-04-20
CA2906057A1 (en) 2014-10-02
HK1212614A1 (zh) 2016-06-17
NZ751452A (en) 2020-04-24
IL240886B (en) 2020-09-30
JP6511609B2 (ja) 2019-05-22
NZ711567A (en) 2020-04-24
KR20190131623A (ko) 2019-11-26
SG11201507475UA (en) 2015-10-29
EP3744345B1 (en) 2022-02-09
EP2968553A1 (en) 2016-01-20
EP3744345A1 (en) 2020-12-02
AU2014243783A1 (en) 2015-10-01
KR20150130395A (ko) 2015-11-23
BR112015022210A8 (pt) 2018-01-23
MY185551A (en) 2021-05-19
CN110538322A (zh) 2019-12-06
ZA202005525B (en) 2022-04-28
US20140314748A1 (en) 2014-10-23
RU2015143607A (ru) 2017-04-20
IL240886A0 (en) 2015-10-29
JP6814962B2 (ja) 2021-01-20
ZA201506981B (en) 2021-03-31
JP2019055962A (ja) 2019-04-11
RU2694055C2 (ru) 2019-07-09
MX2019006633A (es) 2021-12-08
EP2968553B1 (en) 2020-08-12
RU2019120404A (ru) 2019-08-06
KR102048512B1 (ko) 2019-11-26
AR095396A1 (es) 2015-10-14
US10925966B2 (en) 2021-02-23
CN105209069B (zh) 2019-08-23
MY189047A (en) 2022-01-21
US20180280514A1 (en) 2018-10-04
EP2968553A4 (en) 2016-10-19
US10010611B2 (en) 2018-07-03
US20200179516A1 (en) 2020-06-11
IL275103A (en) 2020-07-30
MX365567B (es) 2019-06-07
AU2019201566A1 (en) 2019-03-28
BR112015022210A2 (pt) 2017-10-10
RU2015143607A3 (enExample) 2018-03-20

Similar Documents

Publication Publication Date Title
AU2019201566B2 (en) Antibody formulations
US11370833B2 (en) Antibody formulations
US20200392220A1 (en) Antibody formulation
AU2013202276B2 (en) Antibody formulation
AU2017279638A1 (en) Antibody formulation
HK1212614B (zh) 抗体配制剂

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: GENENTECH, INC.

Free format text: FORMER NAME(S): GENETECH, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired